Código QR

UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer

Background: The KEYNOTE-522 trial showed that use of pembrolizumab-chemotherapy for stage 2-3 triple-negative breast cancer improved pathological complete response (pCR) rates and event-free and overall survival compared with chemotherapy alone. This retrospective multicentre cohort study collated r...

Descripción completa

Guardado en:
Autores principales: J. McKeon, E. Daniels, A. Halstead, C. Machado, S. Potter, T. Strawson-Smith, A. Okines, S. Mcintosh, H. Tovey, T. Robinson, H. Abdallah, S. Ahmed, N. Ainsworth, A. Akhtar, M. Amaya, C. Archer, A. Armstrong, O. Ayodele, A. Ayyad, M. Azhar, K. Ball, B. Baraka, H. Barot, U. Barthakur, A. Borley, R. Bowen, F. Britton, H. Chapman, H. Cook, E. Copson, K. Crawford, N. Cresti, B. Crook, R. Cutress, L. Drewett, K.H. El-Shakankery, L. Glanville, R. Gul, A. Guppy, L. Gurung, V. Harding, C. Harper-Wynne, L. Hennah, S. Ho, J. Howells, T. Irfan, C. Iwu, E. Johnston, S. Khan, J. King, P. Koliou, A. Konstantis, C. Kruppa, A. Lewis, P. Lowdon, T. Lucas, A.L. Smith, K. McAdams, H. McKenzie, C. Michie, T. Nawarathna, D. Nelmes, O. Oikonomidou, O. Omokhodion, C. O’Neill, A. Percival, C. Pow, S. Rana, D. Rea, S. Rehman, H. Sarwar, S. Seymour, A. Shaheen, A. Sheri, R. Simcock, S. Spensley, M.H. Syed Khaja, A. Thomson, L. Uden, L. Walkington, L. Watts, H. Whydle, H. Yusof
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2026-03-01
Colección:ESMO Real World Data and Digital Oncology
Materias:
real-world-evidence
KEYNOTE-522
triple-negative breast cancer
Acceso en línea:http://www.sciencedirect.com/science/article/pii/S2949820125005533
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares